ArticleAdvances in laboratory medicine2026
An algorithm to predict intrathecal IgM synthesis in multiple sclerosis patients: optimizing the use of oligoclonal band testing.
Article in Advances in laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to develop a simple, cost-effective algorithm to predict the presence of oligoclonal IgM bands (OCMB) in patients with multiple sclerosis (MS), using surrogate markers such as the IgM Index (IgMi) and the Free Kappa Light Chains Index (FKLCi), with the aim of reducing the need for OCMB testing while maintaining high diagnostic accuracy. Methods: A retrospective study was conducted using paired serum and cerebrospinal fluid samples from patients diagnosed with MS at disease onset at Hospital Universitari i Politècnic La Fe. Receiver operating characteristic (ROC) curve analyses were performed for IgMi and FKLCi to evaluate their ability to predict OCMB positivity. Several combinations of cutoff values prioritizing high specificity and positive predictive value (PPV) were tested, and the best-performing threshold combination was selected. Results: A total of 97 patients were included. The optimal model defined OCMB positivity as having either IgMi≥0.2 or FKLCi≥250. Applying this algorithm reduced the need for OCMB testing by 33 %, while achieving a specificity of 90 % and a PPV of 85 %. Conclusions: IgMi and FKLCi may serve as reliable predictors of OCMB positivity in MS, potentially reducing unnecessary testing and laboratory workload.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.